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a massive pulmonary embolism and right heart failure and thus a CT
angiography of the chest was performed, demonstrating a large quanti-
ty of pericardial ﬂuid (Fig. 1) and a right side pleural effusion (Fig. 2).
Pulsus paradoxus was then noted on blood pressure measurement. A
cardiac echo exam showed a large amount of pericardial ﬂuid and an
alternating right ventricle and right atrium collapse, conﬁrming the
diagnosis of pericardial tamponade. Pericardiocentesis was performed
and 1 l of bloody pericardial ﬂuid was drained, followed by resolution
of her symptoms. Cytology examination of the ﬂuid was positive forfurther therapy (i.e. sclerotherapy or chemotherapy) and was thus
Introduction
Ovarian carcinoma is, to date, a rare cause of neoplastic pericarditis
and cardiac tamponade. As such, the natural history and the manage-
ment of this life threatening event are ill deﬁned. We describe a
72 year old patient with advanced stage ovarian cancer that suffered
from recurrent pericardial effusion and tamponade.Patient description
A72year old, Ashkenazi, BRCA1 carrier (185Del AG) diagnosedwith
stage IIIC ovarian cancer in 2006, was treated with neoadjuvant
chemotherapy followed by optimal cytoreductive surgery and adjuvant
chemotherapy. In 2008, due to recurrence of the tumor, she underwent a
secondary debulking surgery followed by intraperitoneal chemotherapy.
Two years later recurrent disease was again diagnosed. The patient
refused further chemotherapy and therefore was treated with a PARP
inhibitor (Olaparib) under the course of a clinical trial. 21 months
later she was withdrawn from the trial due to pelvic and abdominal
disease progression and refused further systemic treatment.
2 months following treatment cessation the patient presented with
a two week history of worsening dyspnea. Her vital signs were notable
for tachycardia (HR of 113), tachypnea (20 breaths/min) and her
blood pressure was 119/79. Reduced breath sounds in the base of
the right lung and jugular venous distension were noted on physical
examination. ECG demonstrated low voltage and electrical alternans
(alternating amplitude of the QRS complexes). We initially suspected.
c. This is an open access article undermalignant cells compatible with adenocarcinoma. The patient refused
discharged for community palliative care.
Six weeks later she presented again with progressive weakness,
dyspnea and chest pain. A cardiac echo demonstrated recurrence of a
large pericardial effusion and a repeat pericardiocentesis was per-
formed, this time draining 1.700 l of exudative ﬂuid. The patient again
refused any further treatment and passed away 6 weeks later.Discussion
Cardiac tamponade is a life threatening event caused by accumula-
tion of large amounts of pericardial ﬂuid within a relatively short time.
Physical examination and echocardiography are the primary tools for
diagnosis of cardiac tamponade.
Malignant involvement of the pericardium and cardiac tamponade
can be one of the manifestations of cancer. Among the tumors that me-
tastasize to the pericardium, lung cancer is reported most frequently
(Petersen et al., 2009; Blich et al., 2007; Winter et al., 2002).
Diagnosis of malignant cardiac tamponade can be challenging,
since the symptoms mimic other more frequent complications of ad-
vanced cancer such as pulmonary embolism and respiratory failure
due to lung or pleural metastases. Treatment of malignant tamponade
consists of removing the ﬂuid (pericardiocentesis), preventing its re-
accumulation by local treatment to the pericardium and treating the
underlying malignancy. Methods for preventing re-accumulation
consist of prolonged drainage, forming a pericardial window and
sclerotherapy. Multiple agents can be used for sclerotherapy including
talc, doxycycline and bleomycin, but none of them has shown a clear
advantage over prolonged drainage alone. The choice and combina-
tion of treatment are tailored according to the underlying malignancy
and the patient's status.the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. CT axial view demonstrating a large pericardial effusion (upper arrows) and a right
pleural effusion (lower arrow).
Fig. 2. CT coronal view demonstrating the large pericardial effusion (arrows), note the
relative paucity of ascitic ﬂuid.
Table 1
Ovarian carcinoma complicated by cardiac tamponade — a literature review.
Authors Stage Treatment Outcome
Petersen et al. (2009) Manifested as/with disease
recurrence
IV Recurrent drainage and sclerotherapy, combination chemotherapy Survived 12 months
Blich et al. (2007) IIIC Drainage, recurrence after 1 month, drainage Died 1 week later after
2nd drainage
Lund (1985) IV Catheter drainage for 4 days Died 2.5 months later
Micha et al. (2007) IIIC Pericardial window, retreatment with mitoxantrone injection after recurrence NA
Levitan et al. (1990) IV? Drainage, tetracycline infusion, pericardial radiation and combination chemotherapy Survived 2.5 years
Mäenpää et al. (1988) IIB Drainage and combination chemotherapy Survived 11 months
Donato et al. (1986) III Drainage and tetracycline sclerotherapy Died within 24 h
Lund (1985) III Drainage and tetracycline sclerotherapy Died within 3.5 weeks
Winter et al. (2002) Initial presenting symptom IV Drainage and cytoreductive surgery Died within 23 days
Forslund et al. (1991) IV Drainage and intracardiac Bleomycin, cytoreductive surgery, one course of combination
chemotherapy
Died 14 months later
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complication of advanced ovarian cancer. 10 other cases of malignant
pericardial involvement secondary to ovarian carcinoma have been de-
scribed in the English literature (Petersen et al., 2009; Blich et al., 2007;
Winter et al., 2002; Forslund et al., 1991; Levitan et al., 1990; Micha
et al., 2007; Donato et al., 1986; Lund, 1985; Mäenpää et al., 1988) as
outlined in Table 1. In the majority of cases tamponade is diagnosed
after disease recurrence. It seems that of the cases described (Table 1),
the longer overall survival was achieved in patients that were treated
aggressively with sclerotherapy and systemic chemotherapy. It is note-
worthy that of the 8 cases in which the tamponadewas associated with
disease recurrence the two patients having the longer overall survival
after diagnosis (Levitan et al., 1990; Mäenpää et al., 1988) were
chemotherapy sensitive. This probably reﬂects the systemic nature of
ovarian cancer and the fact that tamponade is many times a complica-
tion of advanced recurrent disease, a setting where patients are often
too sick to be treated by chemotherapy and treatment options have
often been exhausted.
Our patient was on a palliative program and refused any further
treatment after the diagnosis of the ﬁrst episode of malignant cardiac
tamponade, suggesting the natural history of malignant pericardiac
tamponade associated with ovarian carcinoma.
If treated by pericardiocentesis alone with no further therapy
(i.e. sclerotherapy and/or chemotherapy) the pericardial ﬂuid re-
accumulation and the life expectancy seem to be short (6 and
12 weeks respectively in this patient's case). This informationshould be discussed with patients presenting with tamponade and
can assist us in managing this rare complication.
Conclusion
Cardiac tamponade secondary to ovarian cancer is a rare manifesta-
tion of advanced disease. Our case underlines the difﬁculty to correctly
diagnose and the natural history of tamponade in patients with ovarian
cancer. The gynecologic oncologist should be aware of its quick
(6–12 weeks) fatal outcomes and the need to aggressively treat this
life threatening complication.
Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
References
Blich, M., Malkin, L., Kapeliovich, M., 2007. Malignant pericardial tamponade secondary
to papillary serous adenocarcinoma of the ovary. Isr. Med. Assoc. J. 9 (4), 337–338
(Apr).
Donato, D.M., Sevin, B.U., Averette, H.E., 1986. Ovarian adenocarcinoma complicated by
malignant pericarditis. Gynecol. Oncol. 24 (2), 171–176 (Jun).
Forslund, T., Forsén, K.O., Mäenpää, J., 1991. Cardiac tamponade due to ovarian carcinoma.
Arch. Gynecol. Obstet. 248 (3), 161–165.
Levitan, Z., Kaplan, A.L., Gordon, A.N., 1990. Survival after malignant pericardial effusion
and cardiac tamponade in advanced ovarian cancer. South. Med. J. 83 (2), 241–242
(Feb).
Lund, B., 1985. Pericardial effusion in advanced ovarian carcinoma. A literature review
and report of two cases. Acta Obstet. Gynecol. Scand. 64 (5), 443–445.
55I. Feferkorn et al. / Gynecologic Oncology Reports 10 (2014) 53–55Mäenpää, J., Taina, E., Erkkola, R., 1988. Malignant pericardial effusion in ovarian
carcinoma cured by systemic chemotherapy. Gynecol. Oncol. 30 (2), 298–301
(Jun).
Micha, J.P., Goldstein, B.H., Zusman, D., Rettenmaier, M.A., Epstein, H.D., Brown III, J.V.,
2007. Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case
report. J. Reprod. Med. 52 (10), 971–973 (Oct).Petersen, E.E., Shamshirsaz, A.A., Brennan, T.M., Demetroulis, E.M., Goodheart, M.J., 2009.
Malignant pericardial effusion with cardiac tamponade in ovarian adenocarcinoma.
Arch. Gynecol. Obstet. 280 (4), 675–678 (Oct).
Winter III, W.E., Seidman, J., Krivak, T.C., Pujari, S.G., Boice, C.R., Carlson, J.W., 2002.
Papillary serous adenocarcinoma of the ovary diagnosed after malignant pericardial
tamponade and embolic stroke. Gynecol. Oncol. 84 (3), 453–455 (Mar).
